Last updated on August 2017

Single Agent Pembrolizumab in Subjects With Advanced Adrenocortical Carcinoma


Brief description of study

Pembrolizumab is a type of immunotherapy, and the purpose of this study is to find out what effects, good and/or bad, pembrolizumab has on you, and your cancer.

Clinical Study Identifier: NCT02673333

.

Contact Investigators or Research Sites near you

Start Over

Please choose location

View all locations

Diane Reidy-Lagunes, MD

Memorial Sloan Kettering Cancer Center
New York, NY United States
  Connect »